Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Registration Provisions Will Strengthen Chinese Oversight Of Pharma Industry

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State Food and Drug Administration revised its drug registration provisions July 12, improving supervision and tightening approval standards in the wake of widespread concern related to drug safety
Advertisement

Related Content

Simcere's Endu Becomes First Drug To Complete Phase IV Trials Under New Drug Registration Regs
Simcere's Endu Becomes First Drug To Complete Phase IV Trials Under New Drug Registration Regs
More Investment In China’s Health Care System Unveiled During NPC;  Is It Time To Ask Who Will Benefit First And Most?
More Investment In China’s Health Care System Unveiled During NPC;  Is It Time To Ask Who Will Benefit First And Most?
Advertisement
UsernamePublicRestriction

Register

SC066379

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel